What is the clinical evidence from this study?

Study design: Observational. Population: Suspected stroke or TIA (n=586). Intervention: Point of care (POC) CYP2C19 genetic testing. Primary outcome: Test failure rate.

What does this research mean for the field?

Implementing point-of-care CYP2C19 genetic testing in an acute stroke unit is feasible and scalable, with a 0.17% test failure rate, and successfully identifies clopidogrel non-responders to guide immediate antiplatelet therapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the implementation of CYP2C19 point-of-care genetic testing for optimizing clopidogrel therapy after stroke.

May 8, 2026European Stroke JournalOpen Access

POC CYP2C19 testing proves feasible in acute stroke units, identifying ~33% as clopidogrel non-responders.

View Full Paper

Ask AI

Bookmark

Why the study?

NICE recommends CYP2C19 genotype testing to determine clopidogrel suitability after stroke or TIA, prompting evaluation of point-of-care testing implementation at a hyperacute stroke unit.

Does point-of-care CYP2C19 genetic testing optimize antiplatelet prescription in patients with suspected stroke or TIA?

Population

586 patients presenting with suspected stroke or TIA at an NHS Hyperacute Stroke Unit

Design

Implementation study

Key result

Implementing point-of-care CYP2C19 genetic testing in an acute stroke unit was feasible, with a 0.17% test failure rate and identifying 32.5% of patients as clopidogrel non-responders.

Authors

NSNourhan Soliman DSDwaipayan Sen CSCraig Smith

Discussion

Member takes

Overview

POC testing integrates into acute stroke workflows; leaves open whether results should guide antiplatelet therapy to reduce recurrent events.

Key Points

To evaluate the implementation of CYP2C19 point-of-care genetic testing for optimizing clopidogrel therapy after stroke.
CYP2C19 testing introduced in NHS Hyperacute Stroke Unit for patients with suspected stroke or TIA.
Training provided for six stroke assessment nurses and five HCAs to conduct testing.
Analysis performed on 586 patients tested within a specified time frame.
Test failure rate was low at 0.17%.
64-76 minutes was the average time for test completion.
32.5% of patients were identified as clopidogrel non-responders, with 83.7% receiving immediate genetically guided therapy.

Study Design

Type

Observational (n=586)

Multicenter

Structured PICO

Does point-of-care CYP2C19 genetic testing optimize antiplatelet prescription in patients with suspected stroke or TIA?

Population

586 patients presenting with suspected stroke or Transient Ischaemic Attack (TIA) at an NHS Hyperacute Stroke Unit (HASU)

Intervention

Point of care (POC) CYP2C19 genetic testing

Outcome

Feasibility and operational metrics of POC testing (test failure rate, time for test completion, proportion of clopidogrel non-responders, and rate of genetically guided antiplatelet therapy prescription)

Implementation of point-of-care CYP2C19 genetic testing in an acute stroke unit is feasible, scalable, and effectively facilitates immediate, personalized antiplatelet prescribing.

Cite This Study

Soliman et al. (2026) conducted an observational in Suspected stroke or TIA (n=586). Point of care (POC) CYP2C19 genetic testing was evaluated on Test failure rate. Implementing point-of-care CYP2C19 genetic testing in an acute stroke unit was feasible, with a 0.17% test failure rate and identifying 32.5% of patients as clopidogrel non-responders.

synapsesocial.com/papers/69fd7ec6bfa21ec5bbf07117 https://doi.org/10.1093/esj/aakag023.329

View Full Paper

Ask AI

Bookmark

May 8, 2026European Stroke JournalOpen Access

POC CYP2C19 testing proves feasible in acute stroke units, identifying ~33% as clopidogrel non-responders.

View Full Paper

Ask AI

Bookmark

Why the study?

NICE recommends CYP2C19 genotype testing to determine clopidogrel suitability after stroke or TIA, prompting evaluation of point-of-care testing implementation at a hyperacute stroke unit.

Does point-of-care CYP2C19 genetic testing optimize antiplatelet prescription in patients with suspected stroke or TIA?

Population

586 patients presenting with suspected stroke or TIA at an NHS Hyperacute Stroke Unit

Design

Implementation study

Key result

Implementing point-of-care CYP2C19 genetic testing in an acute stroke unit was feasible, with a 0.17% test failure rate and identifying 32.5% of patients as clopidogrel non-responders.

Authors

NSNourhan Soliman DSDwaipayan Sen CSCraig Smith

Discussion

Member takes

Overview

POC testing integrates into acute stroke workflows; leaves open whether results should guide antiplatelet therapy to reduce recurrent events.

Key Points

To evaluate the implementation of CYP2C19 point-of-care genetic testing for optimizing clopidogrel therapy after stroke.
CYP2C19 testing introduced in NHS Hyperacute Stroke Unit for patients with suspected stroke or TIA.
Training provided for six stroke assessment nurses and five HCAs to conduct testing.
Analysis performed on 586 patients tested within a specified time frame.
Test failure rate was low at 0.17%.
64-76 minutes was the average time for test completion.
32.5% of patients were identified as clopidogrel non-responders, with 83.7% receiving immediate genetically guided therapy.

Study Design

Type

Observational (n=586)

Multicenter

Structured PICO

Does point-of-care CYP2C19 genetic testing optimize antiplatelet prescription in patients with suspected stroke or TIA?

Population

586 patients presenting with suspected stroke or Transient Ischaemic Attack (TIA) at an NHS Hyperacute Stroke Unit (HASU)

Intervention

Point of care (POC) CYP2C19 genetic testing

Outcome

Implementation of point-of-care CYP2C19 genetic testing in an acute stroke unit is feasible, scalable, and effectively facilitates immediate, personalized antiplatelet prescribing.

Cite This Study

synapsesocial.com/papers/69fd7ec6bfa21ec5bbf07117 https://doi.org/10.1093/esj/aakag023.329

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark